Immunologic Pathways That Predict Mortality in HIV-Infected Ugandans Initiating Antiretroviral Therapy

The plasma kynurenine/tryptophan (KT) ratio, a marker of adaptive immune defects, strongly predicts mortality during treated human immunodeficiency virus (HIV) disease in Ugandans as compared to US-based populations. Here, the KT ratio and T-cell and plasma biomarkers of immune activation were measured among 535 HIV-infected Ugandans prior to ART initiation and at month 6 of viral suppression. The month 6 KT ratio (adjusted hazard ratio [aHR], 2.74), soluble CD14 level (aHR, 2.32), interleukin 6 level (aHR, 2.34), and D-dimer level (aHR, 1.95) were associated with mortality occurring ≥6 months after ART initiation. The KT ratio remained significantly predictive of mortality even after adjustment for the additional biomarkers, suggesting an independent contribution to clinical outcomes in resource-limited settings.

[1]  Jerome H. Kim,et al.  Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  S. Moestrup,et al.  Plasma Soluble CD163 Level Independently Predicts All-Cause Mortality in HIV-1-Infected Individuals. , 2016, The Journal of infectious diseases.

[3]  M. Siedner,et al.  Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. , 2016, The Journal of infectious diseases.

[4]  J. Mefford,et al.  Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans , 2016, AIDS.

[5]  Jeffrey N. Martin,et al.  Persistent Immune Activation and Carotid Atherosclerosis in HIV-Infected Ugandans Receiving Antiretroviral Therapy. , 2016, The Journal of infectious diseases.

[6]  R. Bollinger,et al.  Pre-cART Elevation of CRP and CD4+ T-Cell Immune Activation Associated With HIV Clinical Progression in a Multinational Case–Cohort Study , 2015, Journal of acquired immune deficiency syndromes.

[7]  H. Lane,et al.  Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.

[8]  C. Yiannoutsos,et al.  Estimation of mortality among HIV-infected people on antiretroviral treatment in East Africa: a sampling based approach in an observational, multisite, cohort study. , 2015, The lancet. HIV.

[9]  M. Lederman,et al.  Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. , 2014, The Journal of infectious diseases.

[10]  M. Lederman,et al.  Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. , 2014, The Journal of infectious diseases.

[11]  Jeffrey N. Martin,et al.  The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. , 2014, The Journal of infectious diseases.

[12]  N. Rigotti,et al.  Tobacco Use Among Adults Initiating Treatment for HIV Infection in Rural Uganda , 2014, AIDS and Behavior.

[13]  S. Bicciato,et al.  Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells , 2011, Nature Immunology.

[14]  J. Fridman,et al.  Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors , 2010, Molecular Cancer Therapeutics.

[15]  B. Baban,et al.  IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells1 , 2009, The Journal of Immunology.